Vandetanib for the treatment of thyroid cancer: An update

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 3, 2014, Pages 469-481

  Karras, Spyridon ^a   Anagnostis, Panagiotis ^b   Krassas, Gerasimos E ^a  

^a PANAGIA GENERAL HOSPITAL   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

Author keywords

Medullary thyroid cancer; Thyroid cancer; Tyrosine kinase inhibitor; Vandetanib

Indexed keywords

EPIDERMAL GROWTH FACTOR; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); THYROID NEOPLASMS; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EPIDERMAL GROWTH FACTOR; HUMANS; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYROID NEOPLASMS; TRANSFECTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84894154856     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.885015     Document Type: Article

References (69)

1. SEER Stat Fact Sheets: Thyroid. National Cancer Institute; Bethesda, MD. 2011. Available from: Http://seer.Cancer. gov/statfacts/html/thyro. html#incidencemortality [Last accessed 10 December 2012]
2. De Lellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon; 2004
3. Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid: A clinicopathologic entity. J Clin Endocrinol Metab 1959;19:152-61
4. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: Management guidelines of the american thyroid association. Thyroid 2009;19:565-612 . This article concerns the recent guidelines of American Thyroid Association regarding MTC.
5. Panigrahi B, Roman SA, Sosa JA. Medullary thyroid cancer: Are practice patterns in the United States discordant from American Thyroid Association guidelines? Ann Surg Oncol 2010;17:1490-8
6. Perez CA, Santos ES, Arango BA, et al. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck 2012;34:736-45 . Important paper which concerns initial information regarding PKI in the treatment of thyroid cancer.
7. Comert M, Baran Y, Saydam G. Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era. Am J Blood Res 2013;3(3):191-200
8. Capp C, Wajner SM, Siqueira DR, et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 2010;20:863-71 . Connection pathways betweenVEGFR-1 and VEGFR-2 in MTC.
9. Cudmore MJ, Hewett PW, Ahmad S, et al. The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nat Commun 2012;3:972
10. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280(6):C1375-86
11. Bando H, Brokelmann M, Toi M, et al. Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. Int J Cancer 2004;111(2):184-91
12. Tian X, Song S, Wu J, et al. Vascular endothelial growth factor: Acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun 2001;286(3):505-12
13. Niwakawa M, Yamaguchi R, Onozawa Y, et al. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. Cancer Sci 2013;104(8):1039-44
14. Vinik AI, Raymond E. Pancreatic neuroendocrine tumors: Approach to treatment with focus on sunitinib. Therap Adv Gastroenterol 2013;6(5):396-411
15. Nguyen LK, Kolch W, Kholodenko BN. When ubiquitination meets phosphorylation: A systems biology perspective of EGFR/MAPK signalling. Cell Commun Signal 2013;11(1):52
16. Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): Where wild things are altered. FEBS J 2013;280(21):5350-70
17. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366(1):2-16
18. Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed Res Int 2013;2013:546318
19. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6
20. Bruns CJ, Kohl G, Guba M, et al. Anti-angiogenic and anti-tumor activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Proc Am Assoc Cancer Res (2nd Edn) 2003;44:604
21. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60 . RET gene involvement in MEN-2A.
22. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab 2008;93:682-7 . RET mutations in sporadic MTC in a cohort study with long follow up (10 years).
23. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 2010;11:962-72
24. Gild ML, Bullock M, Robinson BG, et al. Multikinase inhibitors: A new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011;7:617-24 . This paper provides new information regarding multikinase inhibitors in the treatment of thyroid cancer.
25. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801
26. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42
27. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008;26:4708-13
28. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30
29. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84
30. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19
31. Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer - a phase II study in a UK based population. Eur J Endocrinol 2011;165:315-22
32. Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision:a double-blind, randomized, placebocontrolled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349
33. Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012;19:209-16
34. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260-8
35. Schoffski P, Elisei R, Muller S, et al. EXAM Study Group. An international, double-blind, randomized, placebocontrolled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECISTprogression at baseline 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;30(Suppl 15):5508 . This is the only Phase III study on which FDA based its approval to release the appropriate license for cabozantinib.
36. Center for Drug Evaluation and Research. Application number: 022405Orig1s000. Pharmacology review (s) [online]. Available from: Http://www. accessdata.fda.gov/drugsatfda-docs/nda/2011/022405Orig1s000PharmR.pdf [Accessed 15 September 2013]
37. Benjamin B, Sahu M, Bhatnagar U, et al. Wirksamkeit und verträglichkeit eines pflanzlichen arzneimittels mit kapuzinerkressenkraut und meerrettich bei akuter sinusitis, akuter bronchitis und akuter blasenentzündung im vergleich zu anderen therapien unter den bedingungen der täglichen praxis. Arzneimittelforschung 2012;Apr;62(4):194-201
38. Martin P, Oliver S, Kennedy S-J, et al. Pharmacokinetics of vandetanib: Three phase I studies in healthy subjects. Clin Ther 2012;34(1):221-37
39. Weil A, Martin P, Smith R, et al. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin Pharmacokinet 2010;49(9):607-18
40. European Medicines Agency. Assessment report. Caprelsa. Vandetanib. Procedure no. EMEA/H/C/002315//0000 [online]. Available from: Http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/002315/WC500123603.pdf [Accessed 16 September 2013]
41. Center for Drug Evaluation and Research. Application number: 022405Orig1s000. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from: Http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 022405Orig1s000ClinPharmR. pdf [Accessed 29 February 2012]
42. Wells SA, Robinson BG, Gagel RF. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134-41 . The Phase III trial where vandetanib FDA approval was based.
43. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62(16):4645-55 . Significant data on vandetanib preclinical antitumor activity.
44. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62(24):7284-90
45. Arao T, Fukumoto H, Takeda M, et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 2004;64:9101-4
46. Broutin S, Dupuy C, Caillou B, et al. In vitro and in vivo activity of vandetanib in a human medullary thyroid carcinoma model bearing a RET (C634W) activating mutation (abstract no. 1788). 100th Annual Meeting of the American Association for Cancer Research; Apr Denver (CO); 2009. p. 18-22
47. Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer 2011;18(1):1-11
48. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004;23(36):6056-63
49. Bruns CJ, Shrader M, Harbison MT, et al. Effect of the vascular endothelial growth factor receptor - 2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 2002;102:101-8
50. Bradley DP, Tessier JT, Checkley DR, et al. The VEGF signaling inhibitors ZD6474 and AZD2171 compromise hemodynamic parameters in an SW620 human colon tumor model: An analysis using perfusion-permeability dynamic contrast-enhanced magnetic resonance imaging (pp-DCE-MRI). Proc Am Assoc Cancer Res 2004;45:1051
51. Checkley D, Tessier JJ, Kendrew J, et al. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003;89:1889-95
52. Taguchi F, Koh Y, Koizumi F, et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ('Iressa')-sensitive and resistant xenograft models. Cancer Sci 2004;95:984-9
53. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10:784-93
54. McCarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004;3:1041-8
55. Verbeek HH, Alves MM, de Groot JW, et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 2011;96:E991-5 . Key article on the comparative effects of TKI inhibitors on MTC cell lines.
56. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signalling, in patients with solid, malignant tumors. Ann Oncol 2005;16(8):1391-7
57. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1(9):1002-9
58. Broniscer A, Baker JN, Tagen M, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 2010;28(31):4762-8
59. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95(6):2664-71
60. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28(5):767-72
61. Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res 2013;19(15):4239-48
62. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13(9):897-905 . A Phase II trial with a new under-discussion indication for DTC.
63. Caprelsa (vandetanib) tablets: US prescribing information [online]. Available from: Http://www1. astrazenecaus. com/pi/vandetanib.pdf [Accessed 15 September 2013]
64. Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: A systematic review and meta-analysis. PLoS One 2012; [Epub ahead of print] . Significant data on QTc prolongation after vandetanib treatment.
65. Qi WX, Shen Z, Lin F, et al. Incidence and risk of hypertension with vandetanib in cancer patients: A systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 2013;75(4):919-30
66. Rosen AC, Wu S, Damse A, et al. Risk of rash in cancer patients treated with vandetanib: Systematic review and meta-analysis. J Clin Endocrinol Metab 2012;Apr;97(4):1125-33
67. Brassard M, Neraud B, Trabado S, et al. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab 2011;96(9):2741-9
68. Massicotte MH, Borget I, Broutin S, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroidcarcinoma treated with vandetanib: Results from a placebo-controlled study. J Clin Endocrinol Metab 2013;98(6):2401-8
69. Jovelet C, Deroussent A, Broutin S, et al. Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib. Eur J Drug Metab Pharmacokinet 2013;38(3):149-57